Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by lv_426on Jan 10, 2020 7:17pm
70 Views
Post# 30541006

RE:RE:RE:RE:RE:Share Price (Unbiased Opionion)

RE:RE:RE:RE:RE:Share Price (Unbiased Opionion)
Inv3strr wrote: @lvl426 -  Think it thru... Why do you think the stock is at $0.31 right now? Ill give you the answer.
 
The reason this stock is so undervalued is because there are very few traders that are even capable of buying the stock at this stage. Very few.
 
First, its traded on the TSXV and OTC where the population of traders is small.  In fact there are really very few buyers on those stock exchanges... This isn't the NYSE with millions of traders. Its limited to Canada and some US traders on the OTC.


Of those traders that are on the TSX / OTC, many of them cannot buy even if they wanted to, because it’s a pre-revenue company. No mutual funds are allowed to buy. Many big investment firms within many categories are not allowed to buy.  So that’s a LOT of trading that is completely out.
 
Of the small population of traders that are left, research has shown that most buy shares in ETFs or Indexes. Or they go for "safer" stocks that r well known.  Research also shows that when a trader sees the price has been dropping for along time, they think it’s a bad stock (you are the perfect example.) So that’s a big chunk of buyers that is out. 
 
Very small population left, and even more of them are out…. Its the insiders that own most of the Replicel stock.  BECAUSE they’re insiders they CANT buy any stock because there not allowed ... they are “insiders.” 

So there are not many traders that are left to buy the stock. Just a few of us retailers kicking around. And the retails that are left to buy might not even know about replicel yet.   
 
And that is why this is a completely undervalued stock.
 
What's going to change?    Why will the stock go up? 

It will be revenue generating soon so there will be  institutional investors that will start to take serious interest. I am talking about private investment portfolios that have deep pockets like Chinese and American investors. They love this kind of stock, but they will wait until  just before it goes to market, which is about now.

Also when it is revenue generating it attracts partners that want IN, like medical device companies. And they want to buy stock. 

It will have another Japanese and European partner that will pay for the rights to use the tech and if they dont buy stock there industry will notice and they will. 

The RCI-02 marketing is now being launched and that will create lots of interest generally

Replicel will graduate from TSXV to the TSX so mutual funds and institutions will be allowed to invest
 
ETC. etc. 
 
Just look at other biotech stocks!!! There only needs to be 1 or 2 things to happen in 2020 for the population of buyers to increase AND the stock price to skyrocket.   
 
@lvl426 if you have any stock sell it to me..  I’ll buy it with my loan. 



insiders can absolutely buy stock. There are plenty of sites that track it. Insiders must report buying or selling in a timely manner.
Bullboard Posts